EPS Q/Q spoločnosti Aerie Pharmaceuticals Inc
Aká je hodnota metriky EPS Q/Q spoločnosti Aerie Pharmaceuticals Inc?
Hodnota metriky EPS Q/Q spoločnosti Aerie Pharmaceuticals Inc je -52.24%
Aká je definícia metriky EPS Q/Q?
Štvrťročný rast EPS (Quarterly EPS growth rate) zo štvrťroku na štvrťrok je nárast EPS spoločnosti za posledné štyri štvrťroky v porovnaní s výsledkami z minulých štyroch štvrťrokov.
The earnings per share growth rate is an important factor for judging a company's value. EPS growth rate gives a good picture of the rate at which the company has grown its profitability in respect to the total number of shares. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
EPS Q/Q spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Aerie Pharmaceuticals Inc
Čomu sa venuje spoločnosť Aerie Pharmaceuticals Inc?
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Firmy s metrikou eps q/q podobnou spoločnosti Aerie Pharmaceuticals Inc
- Hodnota metriky EPS Q/Q spoločnosti Kiniksa Pharmaceuticals International Plc je -52.46%
- Hodnota metriky EPS Q/Q spoločnosti Root je -52.41%
- Hodnota metriky EPS Q/Q spoločnosti THL Credit je -52.38%
- Hodnota metriky EPS Q/Q spoločnosti EuroDry je -52.38%
- Hodnota metriky EPS Q/Q spoločnosti Superior Industries International je -52.38%
- Hodnota metriky EPS Q/Q spoločnosti Cellectis je -52.27%
- Hodnota metriky EPS Q/Q spoločnosti Aerie Pharmaceuticals Inc je -52.24%
- Hodnota metriky EPS Q/Q spoločnosti Sap SE je -52.20%
- Hodnota metriky EPS Q/Q spoločnosti Catalent je -52.11%
- Hodnota metriky EPS Q/Q spoločnosti Moelis & Co je -52.10%
- Hodnota metriky EPS Q/Q spoločnosti Flagstar je -52.04%
- Hodnota metriky EPS Q/Q spoločnosti Sabre Corp je -51.92%
- Hodnota metriky EPS Q/Q spoločnosti Ocuphire Pharma je -51.92%